Skip to content
PubMed This is a summary of 15 peer-reviewed journal articles Updated
Cardiology

What is an LVOT Gradient in Hypertrophic Cardiomyopathy?

At a Glance

An LVOT gradient measures how much blood flow is blocked from leaving the heart in hypertrophic cardiomyopathy. Measured in mmHg during an echocardiogram, higher numbers indicate a tighter blockage. A gradient of 30 mmHg or higher diagnoses obstructive HCM and helps guide treatment decisions.

In hypertrophic cardiomyopathy (HCM), a left ventricular outflow tract (LVOT) gradient is a measurement of how much blood flow is blocked as it leaves your heart. A “gradient” simply means the difference in pressure between two areas [1]. When the heart muscle thickens, it can narrow the pathway (the outflow tract) that blood takes to exit the main pumping chamber and reach the rest of the body. The gradient measures the pressure difference before and after this narrow spot; higher numbers indicate a tighter squeeze and more obstruction [2].

What “LVOT Gradient” Means in Plain English

Think of the LVOT as a hallway leading out of your heart’s main pumping chamber (the left ventricle). In HCM, the walls of this hallway can become thick and bulky [2]. When blood tries to rush past this thickened muscle, it has to squeeze through a narrower space. This creates resistance, much like putting your thumb over a garden hose.

Additionally, this altered, fast-moving blood flow often causes a secondary problem: it can suck the heart’s mitral valve into the pathway, further blocking the exit [3]. Cardiologists call this Systolic Anterior Motion (SAM) of the mitral valve [4]. The combination of the thick wall and the mitral valve being pulled into the wrong place creates a dynamic blockage [5].

The “gradient” is the difference in pressure before and after this blockage, measured in millimeters of mercury (mmHg) [1]. The harder the heart has to work to push blood through the narrow opening, the higher the gradient number will be [6]. While a high number can sound alarming, it is primarily a marker of how much the obstruction is causing your daily symptoms—it is just one of several factors your doctor uses to evaluate your overall risk and care plan [7].

How is Your Gradient Measured?

Your LVOT gradient is typically measured during an echocardiogram (an ultrasound of the heart) using a feature called Doppler [1]. Doppler technology bounces sound waves off moving red blood cells to calculate how fast the blood is traveling. Because blood moves faster when forced through a narrow space, the echocardiogram uses this speed to calculate your pressure gradient [1].

What Do the Numbers Mean?

Cardiologists use specific gradient thresholds to diagnose obstruction and make treatment decisions:

  • Under 30 mmHg: This is considered non-obstructive. Even if you have thickened heart muscle, the blood flow out of your heart is not significantly blocked [2].
  • 30 mmHg or higher: This is the diagnostic threshold for obstructive hypertrophic cardiomyopathy (oHCM). A gradient of 30 mmHg or more means there is a clinically significant blockage of blood flow [2].
  • 50 mmHg or higher: This is a crucial threshold for treatment decisions. Having a number this high is common in obstructive HCM, but if you are experiencing symptoms (like shortness of breath, dizziness, or chest pain) despite taking first-line medications like beta-blockers or calcium channel blockers, cardiologists will often consider more advanced therapies [8][6].

If those daily pills don’t provide enough relief, the next step might be targeted medications like cardiac myosin inhibitors (such as mavacamten, which requires a specific safety monitoring program) [9][10]. If medications still do not help, your doctor may discuss invasive septal reduction therapies [11]. These include surgical myectomy (removing a small piece of the thickened muscle and sometimes repairing the mitral valve) or alcohol septal ablation (shrinking the muscle with alcohol) [12]. These procedures are highly effective at lowering the gradient, but are generally reserved for when medications are not enough [8].

Resting vs. Provoked Gradients

You might notice two different gradient numbers on your echo report:

  • Resting gradient: Measured while you are lying quietly on the exam table [13].
  • Provoked gradient: Measured after your heart’s filling or pumping dynamics change. The technician might ask you to bear down (the Valsalva maneuver), which changes the pressure in your chest, or they may have you exercise on a treadmill to make your heart beat faster and harder [13].

Some patients have a normal gradient at rest but a high gradient during these maneuvers. This is called a latent or provokable obstruction [14]. Identifying it is incredibly helpful—it explains why you might feel completely fine while sitting down but get dizzy or short of breath when you exert yourself, stand up quickly, or bear down [15].

Common questions in this guide

What is considered a normal or non-obstructive LVOT gradient?
An LVOT gradient under 30 mmHg is considered non-obstructive. Even if your heart muscle is thickened, this number means the blood flow leaving your heart is not significantly blocked.
What does an LVOT gradient over 50 mmHg mean for my treatment?
A gradient of 50 mmHg or higher indicates significant blood flow blockage. If you have daily symptoms at this level despite taking standard medications, your cardiologist may recommend advanced treatments like cardiac myosin inhibitors or a surgical procedure.
What is the difference between a resting and provoked gradient?
A resting gradient is measured while you are lying still, while a provoked gradient is measured when you exercise or bear down. Many people only experience blood flow blockage and symptoms when their heart works harder, making the provoked measurement essential for an accurate diagnosis.
What causes the blood flow blockage in hypertrophic cardiomyopathy?
The blockage happens because the heart muscle thickens and narrows the exit pathway for blood. This narrowing forces blood to move faster, which can pull the mitral valve into the pathway, creating a dynamic obstruction known as Systolic Anterior Motion (SAM).

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Is my obstruction primarily present at rest, or is it provoked by things like exercise or bearing down?
  2. 2.Does my echocardiogram show Systolic Anterior Motion (SAM) of my mitral valve?
  3. 3.Are my current first-line medications (like beta-blockers) optimized to lower my gradient, or should we adjust the dosage?
  4. 4.If my gradient is over 50 mmHg and I am still symptomatic, am I a candidate for targeted therapies like mavacamten or septal reduction therapy?
  5. 5.How often do we need to repeat an echocardiogram to track whether my gradient is changing?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (15)
  1. 1

    Study design and rationale of EXPLORER-CN: a phase III, randomised, double-blind, placebo-controlled clinical study to evaluate the efficacy and safety of mavacamten in Chinese adults with symptomatic obstructive hypertrophic cardiomyopathy.

    Tian Z, Wang F, Jin W, et al.

    BMJ open 2023; (13(6)):e071473 doi:10.1136/bmjopen-2022-071473.

    PMID: 37336533
  2. 2

    Hypertrophic obstructive cardiomyopathy.

    Veselka J, Anavekar NS, Charron P

    Lancet (London, England) 2017; (389(10075)):1253-1267 doi:10.1016/S0140-6736(16)31321-6.

    PMID: 27912983
  3. 3

    Surgical Management for Systolic Anterior Motion (SAM) of the Mitral Valve in Obstructive Hypertrophic Myopathy.

    Usui A, Mutsuga M

    Annals of thoracic and cardiovascular surgery : official journal of the Association of Thoracic and Cardiovascular Surgeons of Asia 2022; (28(4)):239-248 doi:10.5761/atcs.ra.22-00103.

    PMID: 35851569
  4. 4

    Systolic anterior motion after mitral valve repair: where do we stand in 2015?

    Alfieri O, Lapenna E

    European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery 2015; (48(3)):344-6 doi:10.1093/ejcts/ezv230.

    PMID: 26142473
  5. 5

    Mitral valve and papillary muscle abnormalities in hypertrophic obstructive cardiomyopathy.

    Teo EP, Teoh JG, Hung J

    Current opinion in cardiology 2015; (30(5)):475-82 doi:10.1097/HCO.0000000000000200.

    PMID: 26192489
  6. 6

    Hypertrophic Cardiomyopathy as a Form of Heart Failure with Preserved Ejection Fraction: Diagnosis, Drugs, and Procedures.

    Banthiya S, Check L, Atkins J

    US cardiology 2024; (18()):e17 doi:10.15420/usc.2023.21.

    PMID: 39508003
  7. 7

    Mavacamten: A First-in-class Oral Modulator of Cardiac Myosin for the Treatment of Symptomatic Hypertrophic Obstructive Cardiomyopathy.

    Reyes KRL, Bilgili G, Rader F

    Heart international 2022; (16(2)):91-98 doi:10.17925/HI.2022.16.2.91.

    PMID: 36741099
  8. 8

    The consolidation of surgery for hypertrophic obstructive cardiomyopathy in Asia and the Pacific Rim.

    Quintana E, Mestres CA

    Asian cardiovascular & thoracic annals 2022; (30(1)):5-7 doi:10.1177/02184923211057323.

    PMID: 34747236
  9. 9

    Cardiac Myosin Inhibitors in Hypertrophic Cardiomyopathy: Clinical Advances and Therapeutic Prospects.

    Hou L, Lin B, Ji X, Huang A

    Drug design, development and therapy 2025; (19()):9367-9385 doi:10.2147/DDDT.S555335.

    PMID: 41127363
  10. 10

    Evolving Strategies for the Management of Obstructive Hypertrophic Cardiomyopathy.

    Liang LW, Lumish HS, Sewanan LR, et al.

    Journal of cardiac failure 2024; (30(9)):1136-1153 doi:10.1016/j.cardfail.2024.04.024.

    PMID: 38777216
  11. 11

    Patient Selection for Alcohol Septal Ablation: Does Age Matter?

    Eleid MF, Nishimura RA

    JACC. Cardiovascular interventions 2016; (9(5)):470-1.

    PMID: 26965936
  12. 12

    Septal reduction therapies for obstructive hypertrophic cardiomyopathy: Current strategies and evolving innovations.

    Cui H, Lai Y, Schaff HV

    Trends in cardiovascular medicine 2026; doi:10.1016/j.tcm.2026.02.004.

    PMID: 41654203
  13. 13

    Standardized Goal-Directed Valsalva Maneuver for Assessment of Inducible Left Ventricular Outflow Tract Obstruction in Hypertrophic Cardiomyopathy.

    Kumar S, Van Ness G, Bender A, et al.

    Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography 2018; (31(7)):791-798 doi:10.1016/j.echo.2018.01.022.

    PMID: 29573929
  14. 14

    Provocation of left ventricular outflow tract obstruction using nitrate inhalation in hypertrophic cardiomyopathy: Relation to electromechanical delay.

    Badran HM, Ibrahim WA, Faheem N, et al.

    Global cardiology science & practice 2015; (2015()):15 doi:10.5339/gcsp.2015.15.

    PMID: 26779503
  15. 15

    Routine orthostatic LVOT gradient assessment in patients with basal septal hypertrophy and LVOT flow acceleration at rest: please stand up.

    Sinclair HC, Russhard P, Critoph CH, Steadman CD

    Echo research and practice 2019; (6(1)):K1-K6.

    PMID: 30668520

This page explains LVOT gradients for educational purposes only and does not replace professional medical advice. Always consult your cardiologist to interpret your specific echocardiogram results and discuss treatment options.

Get notified when new evidence is published on Hypertrophic Cardiomyopathy.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.